ABBOTT LABORATORIES (ABT)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$96.69
-2.17%
Investru Score
51.1 / 100
Neutral
Why is ABT moving?
ABT is down 2.17% today, amid an otherwise sideways trend.
Recent coverage: Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Business overview
- The company operates in the pharmaceutical preparations sector.
- It holds a presence in healthcare through pharmaceutical preparations.
These characteristics show that the company is established within a stable healthcare sector, though its overarching business quality depends heavily on balancing manufacturing costs with product demand.
Bull case
Abbott Laboratories could see an upside if top-line revenue growth of 5.7% accelerates while earnings rebound from their recent contraction. A strong balance sheet with low debt-to-equity of 0.19 provides the financial flexibility necessary to invest in growth and improve profitability margins.
Bear case
A bear case scenario involves continued margin contraction compounding the steep -51.3% decline in earnings per share. If technical weakness persists alongside flat valuation multiples, investor sentiment could remain depressed.
ABT’s Investru Score changed -6 points recently. Want to know exactly what changed and why? That’s a Pro feature →
Score breakdown
- Financial Quality
- 64
- Growth
- 31
- Profitability
- 46
- Balance Sheet
- 74
- Valuation
- 68
- Momentum
- 7
Score history
-6.0 over the last 32 days, driven mainly by momentum (-60).
Financial quality
- The return on invested capital stands at 10.5%.
- The return on equity is registered at 12.5%.
- The free cash flow margin is recorded at 16.7%.
- The earnings quality ratio reaches 1.47.
These figures demonstrate decent capital generation and solid cash conversion relative to accounting earnings, though returns remain moderate overall.
- ROIC
- 10.5%
- ROE
- 12.5%
- FCF Margin
- 16.7%
- Free Cash Flow (TTM)
- $7.4B
- Earnings Quality (OCF ÷ Net Income)
- 1.5x
Valuation
- The trailing P/E ratio is unavailable.
- The forward P/E ratio is 17.55.
- The trailing PEG ratio is unavailable.
- The forward PEG ratio is unavailable.
- The median PEG ratio is unavailable.
- The EV-to-EBITDA ratio is 0.16.
- The price-to-sales ratio is 0.
- The free cash flow yield is unavailable.
These available valuation indicators suggest a moderate forward earnings multiple alongside unusual enterprise value metrics that reflect specific capital structure traits.
- P/E (TTM)
- Data unavailable
- Forward P/E
- 17.6x
- PEG (P/E ÷ EPS Growth)
- Data unavailable
- Company Median PEG
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- 0.2x
- FCF Yield
- Data unavailable
Key risks
- Persistent negative earnings growth could weigh further on investor sentiment given the recent -51.3% EPS contraction.(Probability: High · Impact: High)
- Ongoing margin compression, evidenced by the -1.4% margin trend, may continue to erode profitability.(Probability: Medium · Impact: Medium)
- Weak technical momentum, with the RSI at 29.09 and trading below key moving averages, could prolong the sideways or downward price trend.(Probability: High · Impact: Low)
Latest earnings
- Q1 FY26 EPS
- $0.61
- Estimate
- Data unavailable
- Surprise
- Data unavailable
- The year-over-year EPS growth is -51.3%.
- The earnings quality ratio is 1.47.
These figures indicate that while reported earnings have dropped significantly, the earnings that are generated remain well-supported by actual cash flows.
SEC filings
- 10-Q · Q1 FY26 · period ended 2026-03-31Filed 2026-04-29
- 10-K · FY25 · period ended 2025-12-31Filed 2026-02-20
- 10-Q · Q3 FY25 · period ended 2025-09-30Filed 2025-10-29
- 10-Q · Q2 FY25 · period ended 2025-06-30Filed 2025-07-30
- 10-Q · Q1 FY25 · period ended 2025-03-31Filed 2025-04-30
- 10-K · FY24 · period ended 2024-12-31Filed 2025-02-21
- 10-K · FY23 · period ended 2023-12-31Filed 2024-02-16
- 10-K · FY22 · period ended 2022-12-31Filed 2023-02-17
- 10-K · FY21 · period ended 2021-12-31Filed 2022-02-18
Event filings (8-K) aren't covered by this page's data source yet — only 10-K/10-Q are shown above.
Market cap $0 · 52-week range $81.97–$135.37 · market data as of Oct 1, 2026, 4:03 PM ET · latest SEC filing: 2026-04-29
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze ABT with Investru AINot investment advice. Investru AI summarizes public data and AI-generated analysis for informational purposes only.